AGEN - Agenus Stock Trading
News, Short Squeeze, Breakout and More Instantly...
-
Shares of the small-cap immunotherapy company Agenus (NASDAQ: AGEN) were exceedingly volatile over the whole of 2021. Turning to the specifics, Agenus' stock first gained a healthy 55% during the first month of the year, before giving back all of these gains plus another 10%, ac...
-
LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will partici...
-
Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 status Both ORRs and durability of responses are higher than what has been demonstrated with approved therapies for these patients Median duration of response (mDoR) n...